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Abstract
Acute leukemia with coexisting Gilbert’s syndrome treated by allogeneic hematopoietic stem cell transplantation
(allo-HSCT) is rarely reported. Here we described a case whose transaminase levels were almost normal, although
transient hyperbilirubinemia repeatedly happened during chemotherapy.
To the editor:
We have seen a 52-year-old man with AML-FAB M2a
subtype, who had no history of viral hepatitis. He had
history of mild indirect hyperbilirubinemia with normal
transaminase levels after he took paracetamols in the
past two years, and the same phenomenon occurred to
his siblings, children and nephews. He received three
cycles of chemotherapy containing daunorubicin, idaru-
bicin, pirarubicin, cytarabine, and obtained CR in the
first cycle. His bilirubin level was normal before che-
motherapy; however, mild non-hemolytic indirect hyper-
bilirubinemia happened to him during each cycle of
chemotherapy (Figure 1). Neither autoimmune antibo-
dies, nor serology of viral hepatitis were positive. CT
scan revealed that liver parenchyma, gallbladder and bile
duct were all normal. The histopathology of a liver
biopsy showed mild chronic hepatitis and hepatocellular
cholestasis. The expression of UGT1A1 gene was found
to decrease by 20%. The diagnosis of Gilbert’s syndrome
was confirmed.
After 3 cycles of chemotherapy, the patient received
transplantation from his HLA-identical sibling sister who
was also diagnosed to have GS. The conditioning regi-
men included fludarabine and busulfan. Hematopoietic
engraftment was observed on day +11. In the absence of
GVHD, the levels of transaminase and bilirubin were
almost normal within 100 days post-transplantation
(Figure 1). The patient received G-CSF mobilized donor
peripheral lymphocyte transfusion on days + 60 and +90,
respectively. He developed skin rash and abnormal liver
function on day +123 (Figure 1), consistent with grade II
acute GVHD. After one month treatment with Methyl-
prednisolone, tacrolimus and methotrexate, his liver dys-
function gradually returned to normal. At the last follow-
up on day +510, his liver function was still normal, and
he remained leukemia free.
GS is a common condition; its prevalence has been
described in 3-10% of the general population [1]. With
mild symptoms and reversible indirect hyperbilirubine-
mia, most cases of GS remain undiagnosed and they
may become evident after exercise, stress, drug adminis-
tration, prolonged fasting or inter-current diseases [2].
Several drugs have been reported to induce hyperbiliru-
binemia to GS patients, such as paracetamol, nilotinib,
and pazopanib [3,4]. In our case, hyperbilirubinemia
happened to the patient after each cycle of the che-
motherapy, but it did not occur during the conditioning
and within 100 days post-transplantation. This suggests
that anthracyclines and/or cytarabine might be an inhi-
bitor of UGT1A1 enzyme.
Some reports suggest that GS might be a risk factor of
cancer [5,6]. GS with coexisting hematological malig-
nancies including AML has been reported in individuals,
but the incidence of hematological malignancy in GS is
still unknown [1]. Among these cases, just like ours,
non-hemolytic low-grade indirect hyperbilirubinemia
after chemotherapy occurred repeatedly, but it did not
effect the treatment of hematologic malignancies. In
clinical practice, hyperbilirubinemia is suggestive of
hemolysis, drug-induced liver damage or other condi-
tions, but GS is not very frequently considered [2]. In
our case, we initially attributed hyperbilirubinemia to
drug-induced liver damage in the first two cycles of
chemotherapy. * Correspondence: liuqifa628@163.com
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onset of hyperbilirubinemia in GS patients who received
HSCT. Ruiz-Arguelles GJ, et al. [2] reported seven cases
of acute leukemia with coexisting GS, of which 3 patients
accepted chemotherapy alone, 3 cases treated by allo-
HSCT and one received auto-PBSCT. All seven patients
developed indirect hyperbilirubinemia during the course
of their treatment. No patients died from the liver dys-
function. In our case, transaminase and bilirubin levels
were almost normal during the conditioning and within
100 days after transplantation, although indirect hyperbi-
lirubinemia repeatedly happened during chemotherapy
with daunorubicin, idarubicin, and cytarabine prior to
HSCT. This may suggest that fludarabine and busulfan
had low liver toxicity in GS patients [7]. It could also be
possible that phenytoin, an inducer of UGT1A1 activity
used during the conditioning, prevented hyperbilirubine-
mia [8]. It has been reported that UGT1A1 inducers,
including phenobarbital, rifampin and phenytoin, were
used in the diagnosis and treatment of GS [8,9].
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